Special Diabetes Program Reauthorization Act of 2019

Policy initiatives related to the development of a mandatory product listing system of dietary supplement and functional food product labels & information. Policy initiatives on hemp-derived cannabidiol (CBD), supporting actions that will lead to a legal and regulatory pathway to market for hemp-derived CBD products, pertaining to dietary supplements. H.R. 3699 - The Toxic Free Food Act of 2021; to direct the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, to update and clarify its rule on substances generally recognized as safe, and for other purposes. H.R. 2668 - Consumer Protection and Recovery Act H.R. 841 - Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act of 2020. S. 1698 - Hemp Access and Consumer Safety Act (S.) - To decriminalize and deschedule cannabis, to provide for reinvestment in certain persons adversely impacted by the War on Drugs, to provide for expungement of certain cannabis offenses, and for other purposes; all hemp-derived cannabidiol-related provisions. S. 1843/H.R. 3429 - SHOP SAFE Act of 2021 S. 936 - INFORM Consumers Act H.R. 5502 - To require online marketplaces to verify certain information regarding high-volume third party sellers of consumer products on such online marketplaces and to disclose to consumers certain contact and other information regarding such high-volume third party sellers. H.R. 3699 - Toxic Free Food Act of 2021 H.R. 2668 - Consumer Protection and Recovery Act

Client expense: $70,000 · Firm income: Not reported

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE

Policy initiatives related to the development of a mandatory product listing system of dietary supplement and functional food product labels & information. Policy initiatives on hemp-derived cannabidiol (CBD), supporting actions that will lead to a legal and regulatory pathway to market for hemp-derived CBD products, pertaining to dietary supplements. H.R. 3699 - The Toxic Free Food Act of 2021; to direct the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, to update and clarify its rule on substances generally recognized as safe, and for other purposes. H.R. 2668 - Consumer Protection and Recovery Act H.R. 841 - Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act of 2020. S. 1698 - Hemp Access and Consumer Safety Act (S.) - To decriminalize and deschedule cannabis, to provide for reinvestment in certain persons adversely impacted by the War on Drugs, to provide for expungement of certain cannabis offenses, and for other purposes; all hemp-derived cannabidiol-related provisions. S. 1843/H.R. 3429 - SHOP SAFE Act of 2021 S. 936 - INFORM Consumers Act H.R. 5502 - To require online marketplaces to verify certain information regarding high-volume third party sellers of consumer products on such online marketplaces and to disclose to consumers certain contact and other information regarding such high-volume third party sellers. H.R. 3699 - Toxic Free Food Act of 2021 H.R. 2668 - Consumer Protection and Recovery Act

Client expense: $20,000 · Firm income: Not reported

S. 1895 - Lower Health Care Costs Act H.R. 2668 - Special Diabetes Program Reauthorization Act of 2019 H.R. 2680 - Special Diabetes Program for Indians Reauthorization Act of 2019 S. 3937 - Special Diabetes Program for Indians Reauthorization Act of 2020 H.R. 2328 - Reauthorizing and Extending Americas Community Health Act (REACH Act) S. 2543 - The Prescription Drug Pricing Reduction Act of 2019 S. 2199, H.R. 4906 - Insulin Price Reduction Act S. 2004, H.R. 4010 -- Emergency Access to Insulin Act of 2019 H.R. 3 - Lower Drug Costs Now Act of 2019 H.R. 5749 - Affordable Insulin for All Act S. 2855, H.R. 5691 - Insulin Affordability Data Collection Act H.R. 19, S. 3129 - Lower Costs, More Cures Act of 2019 Issues and legislation related to drug pricing, specifically as it relates to insulin. Issues and legislation related to a passthrough of any/all savings to beneficiaries using insulin in Medicare Part D. Issues and legislation related to providing flexibility in the split of a deductible between devices and prescription drugs. Issues related to the importance of preserving health insurance protections for individuals with pre-existing conditions. Issues related to providing (during the COVID-19 emergency period) and preserving (after the COVID-19 emergency period) telehealth/telemedicine flexibilities for individuals with type 1 diabetes. S. 4315/H.R. 6666 - COVID-19 Testing, Reaching, And Contacting Everyone Act (TRACE) Act H.R. 3630 - No Surprises Act

Client expense: $60,000 · Firm income: Not reported

-Ingredient disclosure -Product safety/risk assessment programs -Chemical plant facility safety -EPA's Safer Choice Program -Confidential Business Information (CBI) -Lautenburg Chemical Safety Act Implementation -H.R.2668:Menstrual Products Right to Know Act of 2019 -ACC chemicals management policy coordination -PFAS (Per- and polyfluoroalkyl substances) -Chemicals in diapers and feminine hygiene products -Chemical policy discussions

Client expense: $661,421 · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), Consumer Product Safety Commission (CPSC), Energy, Dept of, Environmental Protection Agency (EPA), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Intl Trade Administration (ITA), Justice, Dept of (DOJ), Natl Security Council (NSC), Office of Science & Technology Policy (OSTP), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Transportation, Dept of (DOT), Treasury, Dept of, U.S. Agency for International Development (USAID), U.S. Customs & Border Protection, U.S. Immigration & Customs Enforcement (ICE), U.S. International Trade Commission (ITC), U.S. Trade Representative (USTR)

-Ingredient disclosure -Product safety/risk assessment programs -Chemical plant facility safety -EPA's Safer Choice Program -Confidential Business Information (CBI) -Lautenburg Chemical Safety Act Implementation -H.R.2668:Menstrual Products Right to Know Act of 2019 -ACC chemicals management policy coordination

Client expense: $662,332 · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), Consumer Product Safety Commission (CPSC), Energy, Dept of, Environmental Protection Agency (EPA), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Intl Trade Administration (ITA), Justice, Dept of (DOJ), Natl Security Council (NSC), Office of Science & Technology Policy (OSTP), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Transportation, Dept of (DOT), Treasury, Dept of, U.S. Agency for International Development (USAID), U.S. Customs & Border Protection, U.S. Immigration & Customs Enforcement (ICE), U.S. International Trade Commission (ITC), U.S. Trade Representative (USTR)

S. 1895 - Lower Health Care Costs Act H.R. 2668 - Special Diabetes Program Reauthorization Act of 2019 H.R. 2680 - Special Diabetes Program for Indians Reauthorization Act of 2019 S. 3937 - Special Diabetes Program for Indians Reauthorization Act of 2020 H.R. 2328 - Reauthorizing and Extending Americas Community Health Act (REACH Act) S. 2543 - The Prescription Drug Pricing Reduction Act of 2019 S. 2199, H.R. 4906 - Insulin Price Reduction Act S. 2004, H.R. 4010 -- Emergency Access to Insulin Act of 2019 H.R. 3 - Lower Drug Costs Now Act of 2019 H.R. 5749 - Affordable Insulin for All Act S. 2855, H.R. 5691 - Insulin Affordability Data Collection Act H.R. 19, S. 3129 - Lower Costs, More Cures Act of 2019 Issues and legislation related to drug pricing, specifically as it relates to insulin. Issues and legislation related to a passthrough of any/all savings to beneficiaries using insulin in Medicare Part D. Issues and legislation related to providing flexibility in the split of a deductible between devices and prescription drugs. Issues related to the importance of preserving health insurance protections for individuals with pre-existing conditions. H.R. 5254 - Diabetic Vision Loss and Blindness Prevention Act of 2019 Issues related to providing (during the COVID-19 emergency period) and preserving (after the COVID-19 emergency period) telehealth/telemedicine flexibilities for individuals with type 1 diabetes. S. 4315/H.R. 6666 - COVID-19 Testing, Reaching, And Contacting Everyone Act (TRACE) Act

Client expense: $70,000 · Firm income: Not reported

-Ingredient Disclosure -Product Safety/Risk Assessment Programs -Chemical Plant Facility Safety -EPA's Safer Choice Program -Confidential Business Information (CBI) -Lautenburg Chemical Safety Act Implementation -HR 2668:Menstrual Products Right to Know Act of 2019

Client expense: $1,088,155 · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), Consumer Product Safety Commission (CPSC), Energy, Dept of, Environmental Protection Agency (EPA), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Intl Trade Administration (ITA), Justice, Dept of (DOJ), Natl Security Council (NSC), Office of Science & Technology Policy (OSTP), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Transportation, Dept of (DOT), Treasury, Dept of, U.S. Agency for International Development (USAID), U.S. Customs & Border Protection, U.S. Immigration & Customs Enforcement (ICE), U.S. International Trade Commission (ITC), U.S. Trade Representative (USTR)

S. 1895 - Lower Health Care Costs Act H.R. 2668 - Special Diabetes Program Reauthorization Act of 2019 H.R. 2680 - Special Diabetes Program for Indians Reauthorization Act of 2019 S. 3937 - Special Diabetes Program for Indians Reauthorization Act of 2020 H.R. 2328 - Reauthorizing and Extending Americas Community Health Act (REACH Act) S. 2543 - The Prescription Drug Pricing Reduction Act of 2019 S. 2199, H.R. 4906 - Insulin Price Reduction Act S. 2004, H.R. 4010 -- Emergency Access to Insulin Act of 2019 H.R. 3 - Lower Drug Costs Now Act of 2019 H.R. 5749 - Affordable Insulin for All Act S. 2855, H.R. 5691 - Insulin Affordability Data Collection Act H.R. 19, S. 3129 - Lower Costs, More Cures Act of 2019 Issues and legislation related to drug pricing, specifically as it relates to insulin. Issues and legislation related to a passthrough of any/all savings to beneficiaries using insulin in Medicare Part D. Issues and legislation related to providing flexibility in the split of a deductible between devices and prescription drugs. Issues related to the importance of preserving health insurance protections for individuals with pre-existing conditions. H.R. 5254 - Diabetic Vision Loss and Blindness Prevention Act of 2019 Issues related to providing (during the COVID-19 emergency period) and preserving (after the COVID-19 emergency period) telehealth/telemedicine flexibilities for individuals with type 1 diabetes. Issues related to hospital inpatient blood glucose monitoring.

Client expense: $110,000 · Firm income: Not reported

-Ingredient Disclosure -Product Safety/Risk Assessment Programs -Chemical Plant Facility Safety -EPA's Safer Choice Program -Confidential Business Information (CBI) -Lautenburg Chemical Safety Act Implementation -HR 2668:Menstrual Products Right to Know Act of 2019

Client expense: $872,120 · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), Consumer Product Safety Commission (CPSC), Energy, Dept of, Environmental Protection Agency (EPA), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Intl Trade Administration (ITA), Justice, Dept of (DOJ), Natl Security Council (NSC), Office of Science & Technology Policy (OSTP), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Transportation, Dept of (DOT), Treasury, Dept of, U.S. Agency for International Development (USAID), U.S. Customs & Border Protection, U.S. Immigration & Customs Enforcement (ICE), U.S. International Trade Commission (ITC), U.S. Trade Representative (USTR)

Issues related to reauthorization of the Department of Energy Fossil Energy Office, including The EFFECT Act . Issues related to pandemic and recovery, including prioritization, supply chain, processes and posture. Issues related to electric sector security including reliability, public/private and cross sector partnerships, information sharing and protections, research and development, cyber resources and education, liability issues, defense critical electric infrastructure, threats and security postures. Issues related to S. 2657, the American Energy Innovation Act (Advanced Geothermal Innovation Leadership Act) S. 2556 Protecting Resources On The Electric grid with Cybersecurity Technology Act of 2019. S. 2333 Energy Cybersecurity Act of 2019. H.R. 5760 Grid Cybersecurity Research & Development Act. H.R. 359/S. 2095: Enhancing Grid Security through Public-Private Partnerships Act. Issues related to federal funding to address utility operational shortfalls as a result of COVID-19. Issues related to a comprehensive energy package, including several areas addressing streamlining the natural gas pipeline permit process; streamline hydropower approval process; improving the critical electric infrastructure; requiring reliability impact statements for major regulations and improving vegetation management within utility rights-of-ways; electric vehicles and EV infrastructure. H.R. 5428 Grid Modernization Research and Development Act of 2019 Leading Infrastructure for Tomorrows America Act (LIFT Act). A bill to improve and modernize American energy infrastructure. H.R. 748 - Coronavirus Aid, Relief, and Economic Stability (CARES) Act H.R. 5718 - legislation to amend the Natural Gas Act to establish FERC refund authority H.R. 5527 - the 21st Century Power Grid Act H.R. 1426 - Timely Review of Infrastructure Act Issues related to an expansion of FERC Jurisdiction. H.R 733/S.199 Leech Lake Band of Ojibwe Reservation Restoration Act. H.R. 4444/S.1931 WAPA Transparence Act. Issues Related the development of the Water Resources Development Act (WRDA). Issues related to electric vehicles (EV) and EV charging infrastructure, including S. 674/H.R. 2616- Clear Corridors Act of 2019, S. 2302 - Americas Transportation and Infrastructure Act of 2019, and H.R. 5545 - NO EXHAUST Act of 2020. Issues related to energy storage (H.R. 2986/S.1602 - Better Energy Storage Technology Act, S. 1593/H.R. 2909 - Promoting Grid Storage Act of 2019 and H.R. 4447 - - Expanding Access to Sustainable Energy Act) Issues related to DOE energy and science research and development programs (S. 2668/H.R. 2668 - solar r&d, S. 2660/H.R. 2660 wind r&d , S. 2714/H.R. 2714 ARPA-E reauthorization)

H.R. 5760 Grid Cybersecurity Research & Development Act Issues related to infrastructure policy. Issues related to unmanned aerial systems. Issues related to energy storage (H.R. 2986/S.1602 - Better Energy Storage Technology Act and S. 1593/H.R. 2909 - Promoting Grid Storage Act of 2019) Issues related to DOE energy and science research and development programs (S. 2668/H.R. 2668 - solar r&d, S. 2660/H.R. 2660 wind r&d , S. 2714/H.R. 2714 ARPA-E reauthorization)

Client expense: $540,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S. 1895 - Lower Health Care Costs Act H.R. 2668 - Special Diabetes Program Reauthorization Act of 2019 H.R. 2680 - Special Diabetes Program for Indians Reauthorization Act of 2019 H.R. 2328 - Reauthorizing and Extending Americas Community Health Act (REACH Act) H.R. 965 - CREATES Act of 2019 S. 2543 - The Prescription Drug Pricing Reduction Act of 2019 S. 2199, H.R. 4906 - Insulin Price Reduction Act S. 2004, H.R. 4010 -- Emergency Access to Insulin Act of 2019 H.R. 3 - Lower Drug Costs Now Act of 2019 S. 2855 - Insulin Affordability Data Collection Act H.R. 19, S. 3129 - Lower Costs, More Cures Act of 2019 Issues and legislation related to drug pricing, specifically as it relates to insulin Issues and legislation related to a passthrough of any/all savings to beneficiaries using insulin in Medicare Part D. Issues and legislation related to providing flexibility in the split of a deductible between devices and prescription drugs Issues related to the importance of preserving health insurance protections for individuals with pre-existing conditions. H.R. 5254 - Diabetic Vision Loss and Blindness Prevention Act of 2019 Issues relates to expanding telehealth under Medicare for the purposes of qualifying visits for insulin pumps and continuous glucose monitors. S. 3548, H.R. 748 - CARES Act

Client expense: $190,000 · Firm income: Not reported

-Ingredient Disclosure -Product Safety/Risk Assessment Programs -Chemical Plant Facility Safety -EPA's Safer Choice Program -Confidential Business Information (CBI) -Lautenburg Chemical Safety Act Implementation -HR 2668: Menstrual Products Right to Know Act of 2019

Client expense: $769,469 · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), Consumer Product Safety Commission (CPSC), Energy, Dept of, Environmental Protection Agency (EPA), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Intl Trade Administration (ITA), Justice, Dept of (DOJ), Natl Security Council (NSC), Office of Science & Technology Policy (OSTP), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Transportation, Dept of (DOT), Treasury, Dept of, U.S. Agency for International Development (USAID), U.S. Customs & Border Protection, U.S. Immigration & Customs Enforcement (ICE), U.S. International Trade Commission (ITC), U.S. Trade Representative (USTR)

S. 1895 - Lower Health Care Costs Act H.R. 2668 - Special Diabetes Program Reauthorization Act of 2019 H.R. 2680 - Special Diabetes Program for Indians Reauthorization Act of 2019 H.R. 2328 - Reauthorizing and Extending Americas Community Health Act (REACH Act) H.R. 965 - CREATES Act of 2019 S. 2543 - The Prescription Drug Pricing Reduction Act of 2019 S. 2199, H.R. 4906 - Insulin Price Reduction Act S. 2004, H.R. 4010 -- Emergency Access to Insulin Act of 2019 H.R. 3 - Lower Drug Costs Now Act of 2019 S. 2855 - Insulin Affordability Data Collection Act H.R. 19, S. 3129 - Lower Costs, More Cures Act of 2019 Issues and legislation related to drug pricing, specifically as it relates to insulin Issues and legislation related to providing flexibility in the split of a deductible between devices and prescription drugs Issues related to the importance of preserving health insurance protections for individuals with pre-existing conditions. H.R. 5254 - Diabetic Vision Loss and Blindness Prevention Act of 2019

Client expense: $120,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S. 192, Community and Public Health Programs Extension Act. Includes 5-year reauthorization of the Special Diabetes Program (SDP), which ADA supports. ADA does not weigh in on other aspects of the legislation. (Lobbyists used: Gwen Rathbun, Meghan Riley) H.R. 2668, the Special Diabetes Program Reauthorization Act of 2019. Reauthorizes the Special Diabetes Program for type 1 diabetes for fiscal years 2020 - 2024 for $200 million per year. Support legislation. (Lobbyists used: Gwen Rathbun, Meghan Riley, Deema Tarazi) H.R. 2680, the Special Diabetes Programs for Indians Reauthorization Act of 2019. Reauthorizes the Special Diabetes Program for Indians for fiscal years 2020 - 2024 for $200 million per year. Support legislation. (Lobbyists used: Gwen Rathbun, Meghan Riley, Deema Tarazi) H.R. 2740, FY 2020 House Departments of Labor, Health and Human Services, and Education and Related Agencies (LHHS) Appropriations. ADA supports funding for the Division of Diabetes Translation and the National Diabetes Prevention Program at the CDC as well as funding for the NIDDK at the NIH. Our efforts are focused on increased funding for both of these agencies. (Lobbyists used: Meghan Riley, Gwen Rathbun, Deema Tarazi) S. 1895, the Lower Health Care Costs Act. Includes 5-year reauthorization of the Special Diabetes Program (SDP), a provision that would end surprise medical billing, and provisions lowering prescription drug costs, which ADA supports. (Lobbyists used: Gwen Rathbun, Robert Goldsmith, Meghan Riley, Deema Tarazi) H.R. 2328, the Reauthorizing and Extending Americas Community Health Act/REACH Act. Includes 4-year reauthorization of the Special Diabetes Program. ADA does not weigh in on other aspects of the legislation. (Lobbyist used: Gwen Rathbun, Deema Tarazi) S. 2474, FY 2020 Defense Appropriations. Support inclusion of diabetes as an eligible research category for the Congressionally Directed Medical Research Program. (Lobbyist used: Gwen Rathbun, Contract Lobbyists)

S. 192, Community and Public Health Programs Extension Act. Includes 5-year reauthorization of the Special Diabetes Program (SDP), which ADA supports. ADA does not weigh in on other aspects of the legislation. H.R. 2668, the Special Diabetes Program Reauthorization Act of 2019. Reauthorizes the Special Diabetes Program for type 1 diabetes for fiscal years 2020 - 2024 for $200 million per year. Support legislation. H.R. 2680, the Special Diabetes Programs for Indians Reauthorization Act of 2019. Reauthorizes the Special Diabetes Program for Indians for fiscal years 2020 - 2024 for $200 million per year. Support legislation. H.R. 2740, FY 2020 House Departments of Labor, Health and Human Services, and Education and Related Agencies (LHHS) Appropriations. ADA supports funding for the Division of Diabetes Translation and the National Diabetes Prevention Program at the CDC as well as funding for the NIDDK at the NIH. Our efforts are focused on increased funding for both of these agencies. H.R.3163/S.2520, FY 2020 House Transportation-HUD Appropriations. ADA supports inclusion of language to direct FAA to disclose the number of pilots with insulin-dependent diabetes who have been issued licenses. S. 1895, the Lower Health Care Costs Act. Includes 5-year reauthorization of the Special Diabetes Program (SDP), a provision that would end surprise medical billing, and provisions lowering prescription drug costs, which ADA supports. H.R. 2328, the Reauthorizing and Extending Americas Community Health Act/REACH Act. Includes 4-year reauthorization of the Special Diabetes Program. ADA does not weigh in on other aspects of the legislation. S. 2474, FY 2020 Defense Appropriations. Support inclusion of diabetes as an eligible research category for the Congressionally Directed Medical Research Program.

Client expense: $80,000 · Firm income: Not reported

S. 192 - Community and Public Health Programs Extension Act S. 1895 - Lower Health Care Costs Act H.R. 2668 - Special Diabetes Program Reauthorization Act of 2019 H.R. 2680 - Special Diabetes Program for Indians Reauthorization Act of 2019 H.R. 965 - CREATES Act of 2019 Issues related to the proposed, Department of Health and Human Services (HHS), changes to the Anti-Kickback statutes safe harbors. Issues and legislation related to drug pricing, specifically as it relates to Insulin. S. 2004 -- Emergency Access to Insulin Act of 2019 Issues related to the importance of preserving health insurance protections for individuals with pre-existing conditions.

Client expense: $620,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S. 192, Community and Public Health Programs Extension Act. Includes 5-year reauthorization of the Special Diabetes Program (SDP), which ADA supports. ADA does not weigh in on other aspects of the legislation. H.R. 2668, the Special Diabetes Program Reauthorization Act of 2019. Reauthorizes the Special Diabetes Program for type 1 diabetes for fiscal years 2020 - 2024 for $200 million per year. Support legislation. H.R. 2680, the Special Diabetes Programs for Indians Reauthorization Act of 2019. Reauthorizes the Special Diabetes Program for Indians for fiscal years 2020 - 2024 for $200 million per year. Support legislation. H.R. 2740, FY 2020 House Departments of Labor, Health and Human Services, and Education and Related Agencies (LHHS) Appropriations. ADA supports funding for the Division of Diabetes Translation and the National Diabetes Prevention Program at the CDC as well as funding for the NIDDK at the NIH. Our efforts are focused on increased funding for both of these agencies. H.R.3163, FY 2020 House Transportation-HUD Appropriations. ADA supports inclusion of language to direct FAA to disclose the number of pilots with insulin-dependent diabetes who have been issued licenses. S. 1895, the Lower Health Care Costs Act. Includes 5-year reauthorization of the Special Diabetes Program (SDP) and provisions lowering prescription drug costs, which ADA supports. ADA does not weigh in on other aspects of the legislation. Issues worked on not yet reflected in legislation: FY 2020 Defense Appropriations. Support inclusion of diabetes as an eligible research category for the Congressionally Directed Medical Research Program

Client expense: $110,000 · Firm income: Not reported

S. 192 - Community and Public Health Programs Extension Act S. 1895 - Lower Health Care Costs Act H.R. 2668 - Special Diabetes Program Reauthorization Act of 2019 H.R. 2680 - Special Diabetes Program for Indians Reauthorization Act of 2019 H.R. 965 - CREATES Act of 2019 Issues related to the proposed, Department of Health and Human Services (HHS), changes to the Anti-Kickback statutes safe harbors. Issues and legislation related to drug pricing, specifically as it relates to Insulin. S. 2004 -- Emergency Access to Insulin Act of 2019 S. 1948 -- Chronic Disease Management Act of 2019 Issues in the House of Representatives related to amending the Internal Revenue Code, with respect to health savings accounts (HSAs), to allow the high deductible health plans required for an HSA to provide care for chronic conditions with no deductible. Issues related to the importance of preserving health insurance protections for individuals with pre-existing conditions.

Client expense: $190,000 · Firm income: Not reported